Array Biopharma, Inc. (ARRY) Reports Q2 Loss of 17c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.30 -3.23%
EPS Growth %: -70.0%
Financial Fact:
Weighted average shares outstanding - diluted (in shares): 145.1M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: -70.0%
Financial Fact:
Weighted average shares outstanding - diluted (in shares): 145.1M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.10 better than the analyst estimate of ($0.27).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Array Technologies (ARRY) PT Lowered to $6 at BMO Capital
- Buy this energy stock after 64% YTD pullback: Mizuho
- BayCom Corp (BCML) Misses Q3 EPS by 46c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
